Remdesivir in Treatment of COVID-19: A Systematic Benefit –Risk Assessment

ConclusionsPreliminary clinical trial results suggest that there may be a favourable benefit –risk profile for remdesivir compared with placebo in severe COVID-19 infection and further data on benefits would strengthen this evaluation. There is limited safety data for remdesivir, which should be obtained in further studies. The current framework summarises the key anticipated benefits and risks for which further data are needed. Ongoing clinical trial data can be incorporated into the framework when available to provide an updated benefit–risk assessment.
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research